01. Executive Summary
02.List of Abbreviations
03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04.Product Profiles
04.1.1 Gazyva/Gazyvaro
04.1.2 MabThera/Rituxan
04.1.3 Arzerra
04.1.4 Treanda
05.Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06.Disease Overview
06.1 Understanding the Disease
06.2 Types of Chronic Lymphocytic Leukemia
06.3 Symptoms
06.4 Diagnosis
06.5 Staging
06.6 Epidemiology
06.7 Management
06.8 Economic Burden
07.Introduction
08.Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09.Pipeline Portfolio
09.1 Key Information on the Major Pipeline Molecules
09.1.1 RG 105 SC Formulation
09.1.2 Obinutuzumab/ Venetoclax
09.1.3 RG 7596 (Polatuzumab vedotin)
09.1.4 RG 7601 (Venetoclax)
10.Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral
11.Market Segmentation by Type of Molecule
11.1 Small Molecules
11.2 Biologics
12.Geographical Segmentation
13.Buying Criteria
14.Market Growth Drivers
15.Drivers and their Impact
16.Market Challenges
17.Impact of Drivers and Challenges
18.Market Trends
19.Trends and their Impact
20.Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 F. Hoffmann-La Roche
20.2.2 Teva Pharmaceutical Industries
20.2.3 Novartis
20.3 Other and Future Prominent Vendors
21.Key Vendor Analysis
21.1 F. Hoffmann-La Roche
21.1.1 Key Facts
21.1.2 Business Overview
21.1.3 Business Segmentation
21.1.4 Business Segmentation by Revenue 2012 and 2013
21.1.5 Sales by Geography
21.1.6 Business Strategy
21.1.7 Key Information
21.1.8 SWOT Analysis
21.2 Novartis
21.2.1 Key Facts
21.2.2 Business Description
21.2.3 Business Segmentation
21.2.4 Revenue by Business Segmentation
21.2.5 Revenue Comparison 2012 and 2013
21.2.6 Sales by Geography
21.2.7 Business Strategy
21.2.8 Key Developments
21.2.9 SWOT Analysis
21.3 Teva Pharmaceutical Industries
21.3.1 Key Facts
21.3.2 Business Overview
21.3.3 Business Segmentation
21.3.4 Revenue by Business Segmentation
21.3.5 Revenue Comparison 2012 and 2013
21.3.6 Revenue Segmentation by Geography
21.3.7 Business Strategy
21.3.8 Key Developments
21.3.9 SWOT Analysis
22.Other Reports in this Series
[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Snapshot of Chronic Lymphocytic Leukemia
Exhibit 3: Type of Chronic Lymphocytic Leukemia
Exhibit 4: Major Diagnostic Procedures to Determine Chronic Lymphocytic Leukemia
Exhibit 5: Other Diagnostic Procedures to Determine Chronic Lymphocytic Leukemia
Exhibit 6: Rai Staging of Chronic Lymphocytic Leukemia
Exhibit 7: Binet Staging of Chronic Lymphocytic Leukemia
Exhibit 8: Management of Chronic Lymphocytic Leukemia
Exhibit 9: Economic Burden of Chronic Lymphocytic Leukemia
Exhibit 10: Global Chronic Lymphocytic Leukemia Therapeutics Market 2014-2019 ($ millions)
Exhibit 11: Key Takeaways: Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 12: Drug Candidates by Stage of Development, in percentage
Exhibit 13: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Route of Administration
Exhibit 14: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Type of Molecules
Exhibit 15: Segmentation of Global Chronic Lymphocytic Leukemia Therapeutics Market by Geography, 2014
Exhibit 16: Drivers of Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 17: Challenges of Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 18: Trends of Global Chronic Lymphocytic Leukemia Therapeutics Market
Exhibit 19: Global Sales and YoY Growth Rate of Rituxan/MabThera 2010-2014 ($ millions)
Exhibit 20: Global Sales and YoY Growth Rate of Treanda 2010-2014 ($ millions)
Exhibit 21: Global Sales and YoY Growth Rate of Arzerra 2010-2014($ millions)
Exhibit 22: Sales and YoY Growth Rate of Arzerra in US 2010-2014 ($ millions)
Exhibit 23: Sales and YoY Growth Rate of Arzerra in Europe 2010-2014 ($ millions)
Exhibit 24: Region-wise Revenue Comparison of Arzerra 2010-2014 ($ millions)
Exhibit 25: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 26: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 27: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 28: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 29: Novartis AG: Business Segmentation
Exhibit 30: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 31: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 32: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 33: Teva Pharmaceutical Industries Ltd.: Business Segmentation
Exhibit 34: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2013
Exhibit 35: Teva Pharmaceutical Industries Ltd.: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 36: Teva Pharmaceutical Industries Ltd.: Revenue by Geographical Segmentation 2013
【掲載企業】
F. Hoffmann-La Roche, Novartis and Teva Pharmaceutical Industries, Actavis, Amgen, Aryogen, Astellas, Bristol-Myers Squibb, Eagle Pharmaceuticals, Eisai, Fresenius Kabi, Genmab, Gilead Sciences, H. Lundbeck, Hospira, idd biotech, Immunomedics, Johnson & Johnson, Mundipharma, Mylan, Noxxon, Ono Pharmaceutical
【資料のキーワード】
慢性リンパ性白血病(CLL)治療薬、白血病、治療、医薬品、パイプライン
【調査方法】
一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)